Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Parkinson's Disease

  Free Subscription

Articles published in Neurobiol Dis

Retrieve available abstracts of 123 articles:
HTML format

Single Articles

    August 2022
  1. WILLIAMS ET, Chen X, Otero PA, Moore DJ, et al
    Understanding the contributions of VPS35 and the retromer in neurodegenerative disease.
    Neurobiol Dis. 2022;170:105768.
    PubMed     Abstract available

  2. ERDMAN HB, Kornilov E, Kahana E, Zarchi O, et al
    Asleep DBS under ketamine sedation: Proof of concept.
    Neurobiol Dis. 2022;170:105747.
    PubMed     Abstract available

    July 2022
  3. TIAN Y, Pan L, Yuan X, Xiong M, et al
    7,8-Dihydroxyflavone ameliorates mitochondrial impairment and motor dysfunction in the alpha-synuclein 1-103 transgenic mice.
    Neurobiol Dis. 2022;169:105736.
    PubMed     Abstract available

  4. RUSSO I, Bubacco L, Greggio E
    LRRK2 as a target for modulating immune system responses.
    Neurobiol Dis. 2022;169:105724.
    PubMed     Abstract available

  5. BURMEISTER AR, Gordevicius J, Paul EN, Houck C, et al
    Maternal Herpesviridae infection during pregnancy alters midbrain dopaminergic signatures in adult offspring.
    Neurobiol Dis. 2022;169:105720.
    PubMed     Abstract available

  6. PAMIES D, Wiersma D, Katt ME, Zhao L, et al
    Human IPSC 3D brain model as a tool to study chemical-induced dopaminergic neuronal toxicity.
    Neurobiol Dis. 2022;169:105719.
    PubMed     Abstract available

    June 2022
  7. RAUSCHENBERGER L, Behnke J, Grotemeyer A, Knorr S, et al
    Age-dependent neurodegeneration and neuroinflammation in a genetic A30P/A53T double-mutated alpha-synuclein mouse model of Parkinson's disease.
    Neurobiol Dis. 2022 Jun 21:105798. doi: 10.1016/j.nbd.2022.105798.
    PubMed     Abstract available

  8. KIM J, Lee J, Kim E, Choi JH, et al
    Dopamine depletion can be predicted by the aperiodic component of subthalamic local field potentials.
    Neurobiol Dis. 2022;168:105692.
    PubMed     Abstract available

    May 2022
  9. VOIGT RM, Wang Z, Brown JM, Engen PA, et al
    Gut microbial metabolites in Parkinson's disease: Association with lifestyle, disease characteristics, and treatment status.
    Neurobiol Dis. 2022 May 30:105780. doi: 10.1016/j.nbd.2022.105780.
    PubMed     Abstract available

  10. SONG B, Feldmann JW, Cao S, Feitosa M, et al
    A Pitx3-deficient developmental mouse model for fine motor, olfactory, and gastrointestinal symptoms of Parkinson's disease.
    Neurobiol Dis. 2022 May 27:105777. doi: 10.1016/j.nbd.2022.105777.
    PubMed     Abstract available

  11. ABDI IY, Ghanem SS, El-Agnaf OM
    Immune-related biomarkers for Parkinson's disease.
    Neurobiol Dis. 2022;170:105771.
    PubMed     Abstract available

  12. KEENEY MT, Hoffman EK, Farmer K, Bodle CR, et al
    NADPH oxidase 2 activity in Parkinson's disease.
    Neurobiol Dis. 2022 May 13:105754. doi: 10.1016/j.nbd.2022.105754.
    PubMed     Abstract available

  13. BARTL M, Xylaki M, Bahr M, Weber S, et al
    Evidence for immune system alterations in peripheral biological fluids in Parkinson's disease.
    Neurobiol Dis. 2022 May 2:105744. doi: 10.1016/j.nbd.2022.105744.
    PubMed     Abstract available

  14. IZCO M, Carlos E, Alvarez-Erviti L
    Impact of endolysosomal dysfunction upon exosomes in neurodegenerative diseases.
    Neurobiol Dis. 2022;166:105651.
    PubMed     Abstract available

    April 2022
  15. MAMAIS A, Kaganovich A, Harvey K
    Convergence of signalling pathways in innate immune responses and genetic forms of Parkinson's disease.
    Neurobiol Dis. 2022;169:105721.
    PubMed     Abstract available

    March 2022
  16. CAMPANELLI F, Natale G, Marino G, Ghiglieri V, et al
    Striatal glutamatergic hyperactivity in Parkinson's disease.
    Neurobiol Dis. 2022 Mar 18:105697. doi: 10.1016/j.nbd.2022.105697.
    PubMed     Abstract available

  17. WEISS F, Labrador-Garrido A, Dzamko N, Halliday G, et al
    Immune responses in the Parkinson's disease brain.
    Neurobiol Dis. 2022;168:105700.
    PubMed     Abstract available

  18. HENDERSON MX, Henrich MT, Geibl FF, Oertel WH, et al
    The roles of connectivity and neuronal phenotype in determining the pattern of alpha-synuclein pathology in Parkinson's disease.
    Neurobiol Dis. 2022 Mar 10:105687. doi: 10.1016/j.nbd.2022.105687.
    PubMed     Abstract available

  19. SHEN W, Zhai S, Surmeier DJ
    Striatal synaptic adaptations in Parkinson's disease.
    Neurobiol Dis. 2022 Mar 7:105686. doi: 10.1016/j.nbd.2022.105686.
    PubMed     Abstract available

  20. COUSINEAU J, Plateau V, Baufreton J, Le Bon-Jego M, et al
    Dopaminergic modulation of primary motor cortex: From cellular and synaptic mechanisms underlying motor learning to cognitive symptoms in Parkinson's disease.
    Neurobiol Dis. 2022 Mar 1:105674. doi: 10.1016/j.nbd.2022.105674.
    PubMed     Abstract available

    February 2022
  21. MOLINET-DRONDA F, Blesa J, Del Rey NL, Juri C, et al
    Cerebral metabolic pattern associated with progressive parkinsonism in non-human primates reveals early cortical hypometabolism.
    Neurobiol Dis. 2022;167:105669.
    PubMed     Abstract available

  22. BOCCALINI C, Carli G, Pilotto A, Padovani A, et al
    Gender differences in dopaminergic system dysfunction in de novo Parkinson's disease clinical subtypes.
    Neurobiol Dis. 2022;167:105668.
    PubMed     Abstract available

  23. GEGG ME, Menozzi E, Schapira AHV
    Glucocerebrosidase-associated Parkinson disease: Pathogenic mechanisms and potential drug treatments.
    Neurobiol Dis. 2022;166:105663.
    PubMed     Abstract available

  24. KASEN A, Houck C, Burmeister AR, Sha Q, et al
    Upregulation of alpha-synuclein following immune activation: Possible trigger of Parkinson's disease.
    Neurobiol Dis. 2022 Feb 7:105654. doi: 10.1016/j.nbd.2022.105654.
    PubMed     Abstract available

    January 2022
  25. HORSAGER J, Knudsen K, Sommerauer M
    Clinical and imaging evidence of brain-first and body-first Parkinson's disease.
    Neurobiol Dis. 2022 Jan 11:105626. doi: 10.1016/j.nbd.2022.105626.
    PubMed     Abstract available

  26. WOERMAN AL, Tamguney G
    Body-first Parkinson's disease and variant Creutzfeldt-Jakob disease - similar or different?
    Neurobiol Dis. 2022 Jan 10:105625. doi: 10.1016/j.nbd.2022.105625.
    PubMed     Abstract available

    December 2021
  27. LI J, Chen L, Qin Q, Wang D, et al
    Upregulated hexokinase 2 expression induces the apoptosis of dopaminergic neurons by promoting lactate production in Parkinson's disease.
    Neurobiol Dis. 2021;163:105605.
    PubMed     Abstract available

  28. CHEN H, Wang K, Scheperjans F, Killinger B, et al
    Environmental triggers of Parkinson's disease - Implications of the Braak and dual-hit hypotheses.
    Neurobiol Dis. 2021;163:105601.
    PubMed     Abstract available

  29. VAN DEN BERGE N, Ulusoy A
    Animal models of brain-first and body-first Parkinson's disease.
    Neurobiol Dis. 2021;163:105599.
    PubMed     Abstract available

  30. SCHILDER BM, Navarro E, Raj T
    Multi-omic insights into Parkinson's Disease: From genetic associations to functional mechanisms.
    Neurobiol Dis. 2021 Dec 3:105580. doi: 10.1016/j.nbd.2021.105580.
    PubMed     Abstract available

  31. NOVELLO S, Mercatelli D, Albanese F, Domenicale C, et al
    In vivo susceptibility to energy failure parkinsonism and LRRK2 kinase activity.
    Neurobiol Dis. 2021 Dec 3:105579. doi: 10.1016/j.nbd.2021.105579.
    PubMed     Abstract available

  32. BORGHAMMER P, Horsager J, Andersen K, Van Den Berge N, et al
    Neuropathological evidence of body-first vs. brain-first Lewy body disease.
    Neurobiol Dis. 2021;161:105557.
    PubMed     Abstract available

    November 2021
  33. HANG L, Wang Z, Foo ASC, Goh GWY, et al
    Conditional disruption of AMP kinase in dopaminergic neurons promotes Parkinson's disease-associated phenotypes in vivo.
    Neurobiol Dis. 2021;161:105560.
    PubMed     Abstract available

  34. NORDSTROM E, Eriksson F, Sigvardson J, Johannesson M, et al
    ABBV-0805, a novel antibody selective for soluble aggregated alpha-synuclein, prolongs lifespan and prevents buildup of alpha-synuclein pathology in mouse models of Parkinson's disease.
    Neurobiol Dis. 2021 Nov 1:105543. doi: 10.1016/j.nbd.2021.105543.
    PubMed     Abstract available

    Alternative platelet activation pathways and their role in neurodegenerative diseases.
    Neurobiol Dis. 2021;159:105512.
    PubMed     Abstract available

  36. JOHNSON ME, Bergkvist L, Stetzik L, Steiner JA, et al
    Heterozygous GBA D409V and ATP13a2 mutations do not exacerbate pathological alpha-synuclein spread in the prodromal preformed fibrils model in young mice.
    Neurobiol Dis. 2021;159:105513.
    PubMed     Abstract available

  37. COSDEN M, Jinn S, Yao L, Gretzula CA, et al
    A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy.
    Neurobiol Dis. 2021;159:105507.
    PubMed     Abstract available

  38. BRENDZA R, Lin H, Stark K, Foreman O, et al
    Genetic ablation of Gpnmb does not alter synuclein-related pathology.
    Neurobiol Dis. 2021;159:105494.
    PubMed     Abstract available

  39. ALBANESE F, Mercatelli D, Finetti L, Lamonaca G, et al
    Constitutive silencing of LRRK2 kinase activity leads to early glucocerebrosidase deregulation and late impairment of autophagy in vivo.
    Neurobiol Dis. 2021;159:105487.
    PubMed     Abstract available

    October 2021
  40. HU S, Tan J, Qin L, Lv L, et al
    Molecular chaperones and Parkinson's disease.
    Neurobiol Dis. 2021;160:105527.
    PubMed     Abstract available

    August 2021
  41. ALANAZI FI, Al-Ozzi T, Kalia SK, Hodaie M, et al
    Neurophysiological responses of globus pallidus internus during the auditory oddball task in Parkinson's disease.
    Neurobiol Dis. 2021 Aug 27:105490. doi: 10.1016/j.nbd.2021.105490.
    PubMed     Abstract available

  42. TORRES ERS, Stanojlovic M, Zelikowsky M, Bonsberger J, et al
    Alpha-synuclein pathology, microgliosis, and parvalbumin neuron loss in the amygdala associated with enhanced fear in the Thy1-aSyn model of Parkinson's disease.
    Neurobiol Dis. 2021;158:105478.
    PubMed     Abstract available

  43. ARKAN S, Ljungberg M, Kirik D, Hansen C, et al
    DNAJB6 suppresses alpha-synuclein induced pathology in an animal model of Parkinson's disease.
    Neurobiol Dis. 2021 Aug 11:105477. doi: 10.1016/j.nbd.2021.105477.
    PubMed     Abstract available

  44. OLSEN AL, Feany MB
    Parkinson's disease risk genes act in glia to control neuronal alpha-synuclein toxicity.
    Neurobiol Dis. 2021 Aug 11:105482. doi: 10.1016/j.nbd.2021.105482.
    PubMed     Abstract available

  45. RODICHKIN AN, Edler MK, McGlothan JL, Guilarte TR, et al
    Behavioral and neurochemical studies of inherited manganese-induced dystonia-parkinsonism in Slc39a14-knockout mice.
    Neurobiol Dis. 2021 Aug 3:105467. doi: 10.1016/j.nbd.2021.105467.
    PubMed     Abstract available

    July 2021
  46. KAKUSA B, Huang Y, Barbosa DAN, Feng A, et al
    Anticipatory human subthalamic area beta-band power responses to dissociable tastes correlate with weight gain.
    Neurobiol Dis. 2021;154:105348.
    PubMed     Abstract available

    June 2021
  47. ANDREOLI L, Abbaszadeh M, Cao X, Cenci MA, et al
    Distinct patterns of dyskinetic and dystonic features following D1 or D2 receptor stimulation in a mouse model of parkinsonism.
    Neurobiol Dis. 2021 Jun 18:105429. doi: 10.1016/j.nbd.2021.105429.
    PubMed     Abstract available

    May 2021
  48. FAUSER M, Ricken M, Markert F, Weis N, et al
    Subthalamic nucleus deep brain stimulation induces sustained neurorestoration in the mesolimbic dopaminergic system in a Parkinson's disease model.
    Neurobiol Dis. 2021 May 24:105404. doi: 10.1016/j.nbd.2021.105404.
    PubMed     Abstract available

  49. TOMKINS JE, Manzoni C
    Advances in protein-protein interaction network analysis for Parkinson's disease.
    Neurobiol Dis. 2021;155:105395.
    PubMed     Abstract available

  50. BRAZHNIK E, Novikov N, McCoy AJ, Ilieva NM, et al
    Early decreases in cortical mid-gamma peaks coincide with the onset of motor deficits and precede exaggerated beta build-up in rat models for Parkinson's disease.
    Neurobiol Dis. 2021 May 14:105393. doi: 10.1016/j.nbd.2021.105393.
    PubMed     Abstract available

  51. WESTON LJ, Cook ZT, Stackhouse TL, Sal MK, et al
    In vivo aggregation of presynaptic alpha-synuclein is not influenced by its phosphorylation at serine-129.
    Neurobiol Dis. 2021;152:105291.
    PubMed     Abstract available

  52. WIEST C, Tinkhauser G, Pogosyan A, He S, et al
    Subthalamic deep brain stimulation induces finely-tuned gamma oscillations in the absence of levodopa.
    Neurobiol Dis. 2021;152:105287.
    PubMed     Abstract available

    April 2021
  53. YIN Z, Zhu G, Zhao B, Bai Y, et al
    Local field potentials in Parkinson's disease: a frequency-based review.
    Neurobiol Dis. 2021 Apr 28:105372. doi: 10.1016/j.nbd.2021.105372.
    PubMed     Abstract available

  54. PETERS OM, Weiss A, Metterville J, Song L, et al
    Genetic diversity of axon degenerative mechanisms in models of Parkinson's disease.
    Neurobiol Dis. 2021 Apr 20:105368. doi: 10.1016/j.nbd.2021.105368.
    PubMed     Abstract available

    March 2021
  55. BRUMBERG J, Kuzkina A, Lapa C, Mammadova S, et al
    Dermal and cardiac autonomic fiber involvement in Parkinson's disease and multiple system atrophy.
    Neurobiol Dis. 2021 Mar 12:105332. doi: 10.1016/j.nbd.2021.105332.
    PubMed     Abstract available

  56. CHU Y, Kordower JH
    GDNF signaling in subjects with minimal motor deficits and Parkinson's disease.
    Neurobiol Dis. 2021 Mar 5:105298. doi: 10.1016/j.nbd.2021.105298.
    PubMed     Abstract available

  57. ZOU L, Zhang X, Xiong M, Meng L, et al
    Asparagine endopeptidase cleaves synaptojanin 1 and triggers synaptic dysfunction in Parkinson's disease.
    Neurobiol Dis. 2021 Mar 4:105326. doi: 10.1016/j.nbd.2021.105326.
    PubMed     Abstract available

  58. CREED RB, Roberts RC, Farmer CB, McMahon LL, et al
    Increased glutamate transmission onto dorsal striatum spiny projection neurons in Pink1 knockout rats.
    Neurobiol Dis. 2021;150:105246.
    PubMed     Abstract available

    February 2021
  59. JIANG M, Tu HT, Zhang K, Zhang W, et al
    Impaired neurogenesis in the hippocampus of an adult VPS35 mutant mouse model of Parkinson's disease through interaction with APP.
    Neurobiol Dis. 2021 Feb 23:105313. doi: 10.1016/j.nbd.2021.105313.
    PubMed     Abstract available

  60. DE MIRANDA BR, Castro SL, Rocha EM, Bodle CR, et al
    The industrial solvent trichloroethylene induces LRRK2 kinase activity and dopaminergic neurodegeneration in a rat model of Parkinson's disease.
    Neurobiol Dis. 2021 Feb 23:105312. doi: 10.1016/j.nbd.2021.105312.
    PubMed     Abstract available

  61. KINNERUP MB, Sommerauer M, Damholdt MF, Schaldemose JL, et al
    Preserved noradrenergic function in Parkinson's disease patients with rest tremor.
    Neurobiol Dis. 2021 Feb 4:105295. doi: 10.1016/j.nbd.2021.105295.
    PubMed     Abstract available

    January 2021
  62. SENCHUK MM, Van Raamsdonk JM, Moore DJ
    Multiple genetic pathways regulating lifespan extension are neuroprotective in a G2019S LRRK2 nematode model of Parkinson's disease.
    Neurobiol Dis. 2021 Jan 12:105267. doi: 10.1016/j.nbd.2021.105267.
    PubMed     Abstract available

  63. BLAUWENDRAAT C, Makarious MB, Leonard HL, Bandres-Ciga S, et al
    A population scale analysis of rare SNCA variation in the UK Biobank.
    Neurobiol Dis. 2021;148:105182.
    PubMed     Abstract available

  64. ANTONAZZO M, Gomez-Urquijo SM, Ugedo L, Morera-Herreras T, et al
    Dopaminergic denervation impairs cortical motor and associative/limbic information processing through the basal ganglia and its modulation by the CB1 receptor.
    Neurobiol Dis. 2021;148:105214.
    PubMed     Abstract available

    December 2020
  65. YANG J, Luo S, Zhang J, Yu T, et al
    Exosome-mediated delivery of antisense oligonucleotides targeting alpha-synuclein ameliorates the pathology in a mouse model of Parkinson's disease.
    Neurobiol Dis. 2020 Dec 6:105218. doi: 10.1016/j.nbd.2020.105218.
    PubMed     Abstract available

    November 2020
  66. ARASARATNAM CJ, Singh-Bains MK, Waldvogel HJ, Faull RLM, et al
    Neuroimaging and neuropathology studies of X-linked dystonia parkinsonism.
    Neurobiol Dis. 2020;148:105186.
    PubMed     Abstract available

  67. AGLIARDI C, Meloni M, Guerini FR, Zanzottera M, et al
    Oligomeric alpha-Syn and SNARE complex proteins in peripheral extracellular vesicles of neural origin are biomarkers for Parkinson's disease.
    Neurobiol Dis. 2020 Nov 17:105185. doi: 10.1016/j.nbd.2020.105185.
    PubMed     Abstract available

  68. UNDERWOOD CF, Parr-Brownlie LC
    Primary motor cortex in Parkinson's disease: Functional changes and opportunities for neurostimulation.
    Neurobiol Dis. 2020 Nov 2:105159. doi: 10.1016/j.nbd.2020.105159.
    PubMed     Abstract available

    October 2020
  69. WILKINS KB, Parker JE, Bronte-Stewart HM
    Gait variability is linked to the atrophy of the Nucleus Basalis of Meynert and is resistant to STN DBS in Parkinson's disease.
    Neurobiol Dis. 2020;146:105134.
    PubMed     Abstract available

    September 2020
  70. BAASKE MK, Kormann E, Holt AB, Gulberti A, et al
    Parkinson's disease uncovers an underlying sensitivity of subthalamic nucleus neurons to beta-frequency cortical input in vivo.
    Neurobiol Dis. 2020 Sep 26:105119. doi: 10.1016/j.nbd.2020.105119.
    PubMed     Abstract available

    August 2020
  71. CUTILLO G, Simon DK, Eleuteri S
    VPS35 and the mitochondria: Connecting the dots in Parkinson's disease pathophysiology.
    Neurobiol Dis. 2020 Aug 24:105056. doi: 10.1016/j.nbd.2020.105056.
    PubMed     Abstract available

    July 2020
  72. PETROZZIELLO T, Mills AN, Vaine CA, Penney EB, et al
    Neuroinflammation and histone H3 citrullination are increased in X-linked Dystonia Parkinsonism post-mortem prefrontal cortex.
    Neurobiol Dis. 2020 Jul 30:105032. doi: 10.1016/j.nbd.2020.105032.
    PubMed     Abstract available

  73. KAM TI, Hinkle JT, Dawson TM, Dawson VL, et al
    Microglia and astrocyte dysfunction in parkinson's disease.
    Neurobiol Dis. 2020 Jul 28:105028. doi: 10.1016/j.nbd.2020.105028.
    PubMed     Abstract available

  74. JOERS V, Masilamoni G, Kempf D, Weiss AR, et al
    Microglia, inflammation and gut microbiota responses in a progressive monkey model of Parkinson's disease: A case series.
    Neurobiol Dis. 2020 Jul 23:105027. doi: 10.1016/j.nbd.2020.105027.
    PubMed     Abstract available

  75. WIEST C, Tinkhauser G, Pogosyan A, Bange M, et al
    Local field potential activity dynamics in response to deep brain stimulation of the subthalamic nucleus in Parkinson's disease.
    Neurobiol Dis. 2020 Jul 15:105019. doi: 10.1016/j.nbd.2020.105019.
    PubMed     Abstract available

  76. LAZAROV E, Hillebrand M, Schroder S, Ternka K, et al
    Comparative analysis of alternating hemiplegia of childhood and rapid-onset dystonia-parkinsonism ATP1A3 mutations reveals functional deficits, which do not correlate with disease severity.
    Neurobiol Dis. 2020 Jul 9:105012. doi: 10.1016/j.nbd.2020.105012.
    PubMed     Abstract available

    June 2020
  77. ZHENG C, Xu Y, Chen G, Tan Y, et al
    Distinct anti-dyskinetic effects of amantadine and group II metabotropic glutamate receptor agonist LY354740 in a rodent model: An electrophysiological perspective.
    Neurobiol Dis. 2020;139:104807.
    PubMed     Abstract available

  78. PELLEGRINI C, Ippolito C, Segnani C, Dolfi A, et al
    Pathological remodelling of colonic wall following dopaminergic nigrostriatal neurodegeneration.
    Neurobiol Dis. 2020;139:104821.
    PubMed     Abstract available

  79. ANAND N, Holcom A, Broussalian M, Schmidt M, et al
    Dysregulated iron metabolism in C. elegans catp-6/ATP13A2 mutant impairs mitochondrial function.
    Neurobiol Dis. 2020;139:104786.
    PubMed     Abstract available

    May 2020
  80. HEATON GR, Landeck N, Mamais A, Nalls MA, et al
    Sequential screening nominates the Parkinson's disease associated kinase LRRK2 as a regulator of Clathrin-mediated endocytosis.
    Neurobiol Dis. 2020 May 17:104948. doi: 10.1016/j.nbd.2020.104948.
    PubMed     Abstract available

  81. HARJUHAAHTO S, Rasila TS, Molchanova SM, Woldegebriel R, et al
    ALS and Parkinson's disease genes CHCHD10 and CHCHD2 modify synaptic transcriptomes in human IPSC-derived motor neurons.
    Neurobiol Dis. 2020 May 8:104940. doi: 10.1016/j.nbd.2020.104940.
    PubMed     Abstract available

  82. ESPADAS I, Keifman E, Palomo-Garo C, Burgaz S, et al
    Beneficial effects of the phytocannabinoid Delta(9)-THCV in L-DOPA-induced dyskinesia in Parkinson's disease.
    Neurobiol Dis. 2020 May 5:104892. doi: 10.1016/j.nbd.2020.104892.
    PubMed     Abstract available

  83. FAUSTINI G, Longhena F, Bruno A, Bono F, et al
    Alpha-synuclein/synapsin III pathological interplay boosts the motor response to methylphenidate.
    Neurobiol Dis. 2020;138:104789.
    PubMed     Abstract available

    April 2020
  84. BENOIT SM, Xu H, Schmid S, Alexandrova R, et al
    Expanding the search for genetic biomarkers of Parkinson's disease into the living brain.
    Neurobiol Dis. 2020 Apr 14:104872. doi: 10.1016/j.nbd.2020.104872.
    PubMed     Abstract available

  85. VINUEZA-GAVILANES R, Inigo-Marco I, Larrea L, Lasa M, et al
    N-terminal acetylation mutants affect alpha-synuclein stability, protein levels and neuronal toxicity.
    Neurobiol Dis. 2020;137:104781.
    PubMed     Abstract available

  86. BAASKE MK, Kramer ER, Meka DP, Engler G, et al
    Parkin deficiency perturbs striatal circuit dynamics.
    Neurobiol Dis. 2020;137:104737.
    PubMed     Abstract available

    March 2020
  87. MOREAU C, Rolland AS, Pioli E, Li Q, et al
    Intraventricular dopamine infusion alleviates motor symptoms in a primate model of Parkinson's disease.
    Neurobiol Dis. 2020 Mar 20:104846. doi: 10.1016/j.nbd.2020.104846.
    PubMed     Abstract available

  88. PEREIRA JB, Hall S, Jalakas M, Grothe MJ, et al
    Longitudinal degeneration of the basal forebrain predicts subsequent dementia in Parkinson's disease.
    Neurobiol Dis. 2020 Mar 4:104831. doi: 10.1016/j.nbd.2020.104831.
    PubMed     Abstract available

    February 2020
  89. AMAN JE, Johnson LA, Sanabria DE, Wang J, et al
    Directional deep brain stimulation leads reveal spatially distinct oscillatory activity in the globus pallidus internus of Parkinson's disease patients.
    Neurobiol Dis. 2020 Feb 20:104819. doi: 10.1016/j.nbd.2020.104819.
    PubMed     Abstract available

  90. FAIVRE F, Sanchez-Catalan MJ, Dovero S, Bido S, et al
    Ablation of the tail of the ventral tegmental area compensates symptoms in an experimental model of Parkinson's disease.
    Neurobiol Dis. 2020 Feb 19:104818. doi: 10.1016/j.nbd.2020.104818.
    PubMed     Abstract available

  91. STOYKA LE, Arrant AE, Thrasher DR, Russell DL, et al
    Behavioral defects associated with amygdala and cortical dysfunction in mice with seeded alpha-synuclein inclusions.
    Neurobiol Dis. 2020;134:104708.
    PubMed     Abstract available

  92. AFGHAH Z, Chen X, Geiger JD
    Role of endolysosomes and inter-organellar signaling in brain disease.
    Neurobiol Dis. 2020;134:104670.
    PubMed     Abstract available

  93. CHEN C, Vincent AE, Blain AP, Smith AL, et al
    Investigation of mitochondrial biogenesis defects in single substantia nigra neurons using post-mortem human tissues.
    Neurobiol Dis. 2020;134:104631.
    PubMed     Abstract available

  94. ALBERQUILLA S, Gonzalez-Granillo A, Martin ED, Moratalla R, et al
    Dopamine regulates spine density in striatal projection neurons in a concentration-dependent manner.
    Neurobiol Dis. 2020;134:104666.
    PubMed     Abstract available

  95. SOLTI K, Kuan WL, Forizs B, Kustos G, et al
    DJ-1 can form beta-sheet structured aggregates that co-localize with pathological amyloid deposits.
    Neurobiol Dis. 2020;134:104629.
    PubMed     Abstract available

  96. YANG SY, Gegg M, Chau D, Schapira A, et al
    Glucocerebrosidase activity, cathepsin D and monomeric alpha-synuclein interactions in a stem cell derived neuronal model of a PD associated GBA1 mutation.
    Neurobiol Dis. 2020;134:104620.
    PubMed     Abstract available

  97. MEZIAS C, Rey N, Brundin P, Raj A, et al
    Neural connectivity predicts spreading of alpha-synuclein pathology in fibril-injected mouse models: Involvement of retrograde and anterograde axonal propagation.
    Neurobiol Dis. 2020;134:104623.
    PubMed     Abstract available

  98. CRESTO N, Gaillard MC, Gardier C, Gubinelli F, et al
    The C-terminal domain of LRRK2 with the G2019S mutation is sufficient to produce neurodegeneration of dopaminergic neurons in vivo.
    Neurobiol Dis. 2020;134:104614.
    PubMed     Abstract available

    January 2020
  99. BANDRES-CIGA S, Diez-Fairen M, Kim JJ, Singleton AB, et al
    Genetics of Parkinson's disease: An introspection of its journey towards precision medicine.
    Neurobiol Dis. 2020 Jan 25:104782. doi: 10.1016/j.nbd.2020.104782.
    PubMed     Abstract available

  100. SCHWAB AD, Thurston MJ, Machhi J, Olson KE, et al
    Immunotherapy for Parkinson's disease.
    Neurobiol Dis. 2020;137:104760.
    PubMed     Abstract available

  101. HULME H, Fridjonsdottir E, Gunnarsdottir H, Vallianatou T, et al
    Simultaneous mass spectrometry imaging of multiple neuropeptides in the brain and alterations induced by experimental parkinsonism and L-DOPA therapy.
    Neurobiol Dis. 2020 Jan 9:104738. doi: 10.1016/j.nbd.2020.104738.
    PubMed     Abstract available

  102. AIME P, Karuppagounder SS, Rao A, Chen Y, et al
    The drug adaptaquin blocks ATF4/CHOP-dependent pro-death Trib3 induction and protects in cellular and mouse models of Parkinson's disease.
    Neurobiol Dis. 2020 Jan 3:104725. doi: 10.1016/j.nbd.2019.104725.
    PubMed     Abstract available

    December 2019
  103. MARMOR O, Rappel P, Valsky D, Bick AS, et al
    Movement context modulates neuronal activity in motor and limbic-associative domains of the human parkinsonian subthalamic nucleus.
    Neurobiol Dis. 2019;136:104716.
    PubMed     Abstract available

  104. HENDERSON MX, Covell DJ, Chung CH, Pitkin RM, et al
    Characterization of novel conformation-selective alpha-synuclein antibodies as potential immunotherapeutic agents for Parkinson's disease.
    Neurobiol Dis. 2019 Dec 11:104712. doi: 10.1016/j.nbd.2019.104712.
    PubMed     Abstract available

  105. CHEN Z, Li G, Liu J
    Autonomic dysfunction in Parkinson's disease: Implications for pathophysiology, diagnosis, and treatment.
    Neurobiol Dis. 2019 Dec 3:104700. doi: 10.1016/j.nbd.2019.104700.
    PubMed     Abstract available

    November 2019
  106. SIKORA J, Kieffer BL, Paoletti P, Ouagazzal AM, et al
    Synaptic zinc contributes to motor and cognitive deficits in 6-hydroxydopamine mouse models of Parkinson's disease.
    Neurobiol Dis. 2019;134:104681.
    PubMed     Abstract available

  107. GIANGRASSO DM, Furlong TM, Keefe KA
    Characterization of striatum-mediated behavior and neurochemistry in the DJ-1 knock-out rat model of Parkinson's disease.
    Neurobiol Dis. 2019 Nov 14:104673. doi: 10.1016/j.nbd.2019.104673.
    PubMed     Abstract available

  108. MAASS F, Michalke B, Willkommen D, Leha A, et al
    Elemental fingerprint: Reassessment of a cerebrospinal fluid biomarker for Parkinson's disease.
    Neurobiol Dis. 2019 Nov 13:104677. doi: 10.1016/j.nbd.2019.104677.
    PubMed     Abstract available

  109. BELVISI D, Pellicciari R, Fabbrini G, Tinazzi M, et al
    Modifiable risk and protective factors in disease development, progression and clinical subtypes of Parkinson's disease: What do prospective studies suggest?
    Neurobiol Dis. 2019;134:104671.
    PubMed     Abstract available

  110. MILLOT M, Saga Y, Duperrier S, Metereau E, et al
    Prior MDMA administration aggravates MPTP-induced Parkinsonism in macaque monkeys.
    Neurobiol Dis. 2019 Nov 2:104643. doi: 10.1016/j.nbd.2019.104643.
    PubMed     Abstract available

    October 2019
  111. AFLAKI E, Stubblefield BK, McGlinchey RP, McMahon B, et al
    A characterization of Gaucher iPS-derived astrocytes: Potential implications for Parkinson's disease.
    Neurobiol Dis. 2019 Oct 26:104647. doi: 10.1016/j.nbd.2019.104647.
    PubMed     Abstract available

  112. ROCHA EM, De Miranda BR, Castro S, Drolet R, et al
    LRRK2 inhibition prevents endolysosomal deficits seen in human Parkinson's disease.
    Neurobiol Dis. 2019 Oct 13:104626. doi: 10.1016/j.nbd.2019.104626.
    PubMed     Abstract available

    September 2019
  113. RUSSO I, Kaganovich A, Ding J, Landeck N, et al
    Transcriptome analysis of LRRK2 knock-out microglia cells reveals alterations of inflammatory- and oxidative stress-related pathways upon treatment with alpha-synuclein fibrils.
    Neurobiol Dis. 2019;129:67-78.
    PubMed     Abstract available

  114. FENYI A, Leclair-Visonneau L, Clairembault T, Coron E, et al
    Detection of alpha-synuclein aggregates in gastrointestinal biopsies by protein misfolding cyclic amplification.
    Neurobiol Dis. 2019;129:38-43.
    PubMed     Abstract available

    August 2019
  115. STEFANI A, Galati S
    PPN-DBS: A utopic vision or a realistic perspective?
    Neurobiol Dis. 2019;128:1-2.

  116. STEFANI A, Grandi LC, Galati S
    Deep brain stimulation of the pedunculopontine nucleus modulates subthalamic pathological oscillations.
    Neurobiol Dis. 2019;128:49-52.
    PubMed     Abstract available

  117. GUT NK, Mena-Segovia J
    Dichotomy between motor and cognitive functions of midbrain cholinergic neurons.
    Neurobiol Dis. 2019;128:59-66.
    PubMed     Abstract available

  118. NOWACKI A, Galati S, Ai-Schlaeppi J, Bassetti C, et al
    Pedunculopontine nucleus: An integrative view with implications on Deep Brain Stimulation.
    Neurobiol Dis. 2019;128:75-85.
    PubMed     Abstract available

  119. DI GIOVANNI G, Chagraoui A, Puginier E, Galati S, et al
    Reciprocal interaction between monoaminergic systems and the pedunculopontine nucleus: Implication in the mechanism of L-DOPA.
    Neurobiol Dis. 2019;128:9-18.
    PubMed     Abstract available

  120. GARCIA-RILL E, Mahaffey S, Hyde JR, Urbano FJ, et al
    Bottom-up gamma maintenance in various disorders.
    Neurobiol Dis. 2019;128:31-39.
    PubMed     Abstract available

    July 2019
  121. FISCHER P, Pogosyan A, Green AL, Aziz TZ, et al
    Beta synchrony in the cortico-basal ganglia network during regulation of force control on and off dopamine.
    Neurobiol Dis. 2019;127:253-263.
    PubMed     Abstract available

    January 2019
  122. MELLONE M, Zianni E, Stanic J, Campanelli F, et al
    NMDA receptor GluN2D subunit participates to levodopa-induced dyskinesia pathophysiology.
    Neurobiol Dis. 2019;121:338-349.
    PubMed     Abstract available

  123. GUNDNER AL, Duran-Pacheco G, Zimmermann S, Ruf I, et al
    Path mediation analysis reveals GBA impacts Lewy body disease status by increasing alpha-synuclein levels.
    Neurobiol Dis. 2019;121:205-213.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Parkinson's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.